Renal Cell Carcinoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Surgical Management of Renal Cell Carcinoma Extending Into Venous System: A 20-Year Experience. - UroToday



Surgical Management of Renal Cell Carcinoma Extending Into Venous System: A 20-Year Experience. 
UroToday
The purpose of this study is to report our 20-year experience with the surgical management of renal cell carcinoma extending into the inferior vena cava using a novel classification system. We retrospectively reviewed the data of 103 patients (69 males ...

 


Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma 
Cancer Therapy Advisor
Unlike with some other solid tumors, there are not many targetable mutations found in renal cell carcinoma (RCC). ?Having biomarkers for prognosis is important, but at the end of the day patients and physicians want to know what we can do differently ...

 


Optimizing Adjuvant Therapy in Renal Cell Carcinoma - OncLive



OncLive
 
Optimizing Adjuvant Therapy in Renal Cell Carcinoma 
OncLive
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy [published online October 10, 2016]. N Engl J Med. doi: 10.1056/NEJMoa1611406. Hass NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic ...

and more » 


FDA Approves Sunitinib for Recurrent Renal Cell Carcinoma - Cancer Network



Cancer Network
 
FDA Approves Sunitinib for Recurrent Renal Cell Carcinoma 
Cancer Network
The FDA approval was based on the S-TRAC trial, a multicenter, international, double-blind, placebo-controlled, phase III trial of sunitinib in 615 patients with high risk of recurrent renal cell carcinoma after nephrectomy. Patients were randomized 1 ...
Pfizer's Drug Approved As Adjuvant Treatment In Recurrent Renal Cell Carcinoma Pharmaceutical Processing
FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma Cancer Therapy Advisor
FDA approves adjuvant indication for Sutent in renal cell carcinoma The Cancer Letter Publications
Pharmacy Practice News  -FiercePharma  -Rare Disease Report 
all 26 news articles » 


Adjuvant Renal Cell Carcinoma Drug Receives FDA Greenlight - Specialty Pharmacy Times



Medscape
 
Adjuvant Renal Cell Carcinoma Drug Receives FDA Greenlight 
Specialty Pharmacy Times
?This is the first adjuvant treatment approved for patients with renal cell carcinoma, which is significant because patients with this disease who have a nephrectomy are often at high risk of the cancer returning,? said Richard Pazdur, MD, director of ...
FDA Approves Adjuvant Sunitinib for High-Risk RCC OncLive
FDA OKs First Adjuvant Treatment for Kidney Cancer Medscape
FDA approves Sutent to reduce risk for recurrent kidney cancer Healio
Journal of Clinical Pathways 
all 10 news articles » 


Expression of minichromosome maintenance genes in renal cell carcinoma - Dove Medical Press



Expression of minichromosome maintenance genes in renal cell carcinoma 
Dove Medical Press
Abstract: Minichromosome maintenance (MCM) proteins play an essential role in DNA replication. They have been shown to be overexpressed in various types of cancer. However, the role of this family in renal cell carcinoma (RCC) is widely unknown. In ...

 


Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma 
Cancer Therapy Advisor
Previous studies have supported the use of targeted monotherapies with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKI) in the treatment of patients with metastatic renal cell carcinoma (mRCC), according to an oral presentation ...

 


Nivolumab active in metastatic non-clear cell renal cell carcinoma - Healio



Nivolumab active in metastatic non-clear cell renal cell carcinoma 
Healio
MIAMI ? Nivolumab monotherapy demonstrated antitumor activity in a heterogenous population of patients with non-clear cell renal cell carcinoma, according to retrospective study results presented at International Kidney Cancer Symposium. Nivolumab ...

and more » 


Location of bone metastasis may affect outcomes in metastatic renal cell carcinoma - Healio



Location of bone metastasis may affect outcomes in metastatic renal cell carcinoma 
Healio
MIAMI ? Patients with metastatic renal cell carcinoma who had vertebral metastasis achieved significantly shorter survival than patients who had nonvertebral metastasis, according to results of a small study presented at International Kidney Cancer ...

and more » 


Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma - OncLive



Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma 
OncLive
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma. Several new treatment combinations are being ...

and more »